These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 22492501

  • 21. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
    Smith BJ, Bu SY, Wang Y, Rendina E, Lim YF, Marlow D, Clarke SL, Cullen DM, Lucas EA.
    Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
    [Abstract] [Full Text] [Related]

  • 22. PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization.
    Misof BM, Roschger P, Dempster DW, Zhou H, Bilezikian JP, Klaushofer K, Rubin MR.
    J Bone Miner Res; 2016 Jan; 31(1):180-9. PubMed ID: 26111772
    [Abstract] [Full Text] [Related]

  • 23. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.
    Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, Majumdar S, Rosen CJ, PTH Once-Weekly Research (POWR) Group.
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2166-72. PubMed ID: 18349061
    [Abstract] [Full Text] [Related]

  • 24. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine.
    Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY.
    J Bone Miner Res; 2007 Feb; 22(2):260-73. PubMed ID: 17087625
    [Abstract] [Full Text] [Related]

  • 25. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 26. PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation.
    Theman TA, Collins MT, Dempster DW, Zhou H, Reynolds JC, Brahim JS, Roschger P, Klaushofer K, Winer KK.
    J Bone Miner Res; 2009 May; 24(5):964-73. PubMed ID: 19063686
    [Abstract] [Full Text] [Related]

  • 27. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety.
    Cusano NE, Rubin MR, McMahon DJ, Zhang C, Ives R, Tulley A, Sliney J, Cremers SC, Bilezikian JP.
    J Clin Endocrinol Metab; 2013 Jan; 98(1):137-44. PubMed ID: 23162103
    [Abstract] [Full Text] [Related]

  • 28. Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.
    Xu M, Choudhary S, Voznesensky O, Gao Q, Adams D, Diaz-Doran V, Wu Q, Goltzman D, Raisz LG, Pilbeam CC.
    Bone; 2010 Aug; 47(2):341-52. PubMed ID: 20471507
    [Abstract] [Full Text] [Related]

  • 29. A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study.
    Horwitz MJ, Augustine M, Khan L, Martin E, Oakley CC, Carneiro RM, Tedesco MB, Laslavic A, Sereika SM, Bisello A, Garcia-Ocaña A, Gundberg CM, Cauley JA, Stewart AF.
    J Bone Miner Res; 2013 Nov; 28(11):2266-76. PubMed ID: 23661240
    [Abstract] [Full Text] [Related]

  • 30. Bone imaging in hypoparathyroidism.
    Silva BC, Rubin MR, Cusano NE, Bilezikian JP.
    Osteoporos Int; 2017 Feb; 28(2):463-471. PubMed ID: 27577725
    [Abstract] [Full Text] [Related]

  • 31. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats.
    Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR.
    Endocrinology; 1993 Apr; 132(4):1577-84. PubMed ID: 8462456
    [Abstract] [Full Text] [Related]

  • 32. Effect of Endogenous Parathyroid Hormone on Bone Geometry and Skeletal Microarchitecture.
    Hong AR, Lee JH, Kim JH, Kim SW, Shin CS.
    Calcif Tissue Int; 2019 Apr; 104(4):382-389. PubMed ID: 30659307
    [Abstract] [Full Text] [Related]

  • 33. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism.
    Winer KK, Yanovski JA, Cutler GB.
    JAMA; 1996 Aug 28; 276(8):631-6. PubMed ID: 8773636
    [Abstract] [Full Text] [Related]

  • 34. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD.
    J Bone Miner Res; 2000 May 28; 15(5):944-51. PubMed ID: 10804025
    [Abstract] [Full Text] [Related]

  • 35. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
    Sikjaer T, Amstrup AK, Rolighed L, Kjaer SG, Mosekilde L, Rejnmark L.
    J Bone Miner Res; 2013 Oct 28; 28(10):2232-43. PubMed ID: 23649554
    [Abstract] [Full Text] [Related]

  • 36. Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity.
    Gafni RI, Langman CB, Guthrie LC, Brillante BA, James R, Yovetich NA, Boyce AM, Collins MT.
    J Bone Miner Res; 2018 Oct 28; 33(10):1741-1747. PubMed ID: 29878514
    [Abstract] [Full Text] [Related]

  • 37. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY.
    Calcif Tissue Int; 2006 Oct 28; 79(4):262-72. PubMed ID: 16969596
    [Abstract] [Full Text] [Related]

  • 38. Effects of Parathyroid Hormone Administration on Bone Strength in Hypoparathyroidism.
    Rubin MR, Zwahlen A, Dempster DW, Zhou H, Cusano NE, Zhang C, Müller R, Bilezikian JP.
    J Bone Miner Res; 2016 May 28; 31(5):1082-8. PubMed ID: 26724790
    [Abstract] [Full Text] [Related]

  • 39. Use of parathyroid hormone in hypoparathyroidism.
    Cusano NE, Rubin MR, Irani D, Sliney J, Bilezikian JP.
    J Endocrinol Invest; 2013 Dec 28; 36(11):1121-7. PubMed ID: 24445125
    [Abstract] [Full Text] [Related]

  • 40. Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism.
    Winer KK, Kelly A, Johns A, Zhang B, Dowdy K, Kim L, Reynolds JC, Albert PS, Cutler GB.
    J Pediatr; 2018 Dec 28; 203():391-399.e1. PubMed ID: 30470382
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.